Cardiovascular and kidney outcomes of linagliptin treatment in older people with type 2 diabetes and established cardiovascular disease and/or kidney disease: A prespecified subgroup analysis of the randomized, placebo-controlled CARMELINA® trial.
Mark E CooperJulio RosenstockTakashi KadowakiYutaka SeinoChristoph WannerSven SchnaidtDouglas ClarkOdd Erik Johansennull nullPublished in: Diabetes, obesity & metabolism (2020)
Linagliptin did not increase risk for cardiovascular events or hypoglycaemia and kidney function remained stable in older people with T2D and established CVD with albuminuria and/or kidney disease.
Keyphrases
- cardiovascular events
- phase iii
- placebo controlled
- cardiovascular disease
- double blind
- phase ii
- open label
- clinical trial
- coronary artery disease
- study protocol
- type diabetes
- randomized controlled trial
- physical activity
- phase ii study
- cardiovascular risk factors
- metabolic syndrome
- community dwelling
- skeletal muscle
- combination therapy
- smoking cessation